Research Article
Quinoline and Quinazoline Alkaloids against COVID-19: An In Silico Multitarget Approach
Table 1
Toxicity risks and drug likeliness predicted by OSIRIS Property Explorer.
| No. | Compound name | ME | TE | IE | RE | DL | DS |
| 1 | Uranidine | — | — | — | — | 0.50 | 0.78 | 2 | 1-Methyl-2-[6′-(3″,4″-methylenedioxyphenyl)hexyl]-4-quinolone | — | — | — | — | −0.86 | 0.55 | 3 | 4-Methoxy-1-methylquinolin-2-one | — | — | — | — | 1.90 | 0.89 | 4 | 2-Acetyl-4(3H)-quinazolinone | — | — | — | — | 3.11 | 0.94 | 5 | Chimanine D | — | — | — | — | −0.28 | 0.66 | 6 | Cuspareine | — | — | — | — | 4.79 | 0.69 | 7 | Galipeine | — | — | — | — | 3.54 | 0.79 | 8 | Galipinine | — | — | — | — | 2.45 | 0.59 | 9 | Acronydine | — | — | — | — | 2.76 | 0.86 | 10 | Veprisine | — | — | — | — | 2.76 | 0.86 | 11 | Isofebrifugine | — | — | — | — | 4.19 | 0.91 | 12 | 2-Methoxyrutaecarpine | — | — | — | — | 5.25 | 0.8 | 13 | 2-Methoxy-13-methylrutaecarpine | — | — | — | — | 6.09 | 0.81 | 14 | Tryptanthrin | — | — | — | — | 3.28 | 0.84 | 15 | Neosartoryadin A | — | — | — | — | 3.32 | 0.71 | 16 | Neosartoryadin B | — | — | — | — | 1.15 | 0.63 | 17 | Oxoglyantrypine | — | — | — | — | 4.00 | 0.87 | 18 | Norquinadoline A | — | — | — | — | 7.04 | 0.74 | 19 | Deoxynortryptoquivaline | — | — | — | — | 4.44 | 0.66 | 20 | Quinadoline A | — | — | — | — | 7.19 | 0.72 | 21 | 3-Hydroglyantrypine | — | — | — | — | 4.2 | 0.89 | 22 | Cladoquinazoline | — | — | — | — | 3.91 | 0.82 | 23 | Epi-cladoquinazoline | — | — | — | — | 3.91 | 0.82 | 24 | Glyantrypine | — | — | — | — | 3.84 | 0.89 | 25 | Deoxytrytoquivaline | — | — | — | — | 5.93 | 0.58 | 26 | Prelapatine B | — | — | — | — | 3.72 | 0.88 | 27 | Waltherione A | — | — | — | — | −0.01 | 0.54 |
|
|
ME: mutagenic effect; TE: tumorigenic effect; IE: irritant effect; RE: reproductive effect; DL: drug likeliness; DS: drug score; (—): no risk.
|